BHC · Bausch Health Companies

The thesis

Bausch Health's recovery is backed by reported results: the third-quarter report on 28 October 2026 beat estimates and raised 2026 guidance for the second time. Debt principal of $20.2 billion still leaves the equity highly sensitive to small changes in the company's value. The fourth-quarter report, expected in early 2027, settles whether the raised guidance holds through the fourth-quarter headwinds management itself described.

The shares closed at $8.35 on 11 November 2026, 7.6% below the 52-week intraday high of $9.04 set on 29 October 2026. They are up 31.7% over three months (adjusted daily closes). The 50-day average is $6.51 and the 200-day average is $5.77, both as of the 11 November 2026 close.

Third-quarter adjusted earnings per share were $1.77 against a $1.29 consensus, and sales were $2.941 billion against $2.757 billion (Benzinga, 28 October 2026). Adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation, with company adjustments) excluding Bausch + Lomb reached $1,022 million, the first quarter above $1 billion, per the company's release.

Bullish and bearish views on Bausch Health Companies Inc

The bull case on Bausch Health Companies Inc (BHC), in brief: guidance raised for a second time. The bear case: debt remains the dominant fact.

Bull case

• Guidance raised for a second time. The 28 October 2026 8-K lifted adjusted EBITDA guidance excluding Bausch + Lomb to $3.225–3.275 billion, from $3.025–3.100 billion. Revenue guidance excluding Bausch + Lomb rose to $5.525–5.625 billion.
• Consolidated results beat. Third-quarter revenue rose 10% to $2.941 billion, and consolidated adjusted EBITDA attributable to Bausch Health was $1,305 million against $986 million a year earlier (company release, 28 October 2026). Consolidated 2026 revenue guidance moved to $10.975–11.175 billion from $10.790–11.040 billion, against a $10.927 billion estimate (Benzinga).
• A near-term maturity is being retired. Cash was $2,485 million at 30 September 2026, and on 28 October 2026 the company said it will redeem about $643 million of its 8.500% senior notes due 2027 with cash on hand. Total debt at principal was $20,168 million at 30 September 2026, against $20,239 million at 30 June 2026.
• Analyst targets are moving up. RBC Capital raised its target to $10 from $9 with a Sector Perform rating and Jefferies raised its to $8 with a Hold rating on 29 October 2026. Barclays raised its target to $9 with an Equal-Weight rating on 11 November 2026 (Benzinga).
• Salix is generating clinical data. Salix presented new cirrhosis and alcohol-associated hepatitis data at The Liver Meeting, held 5 November to 9 November 2026 (Benzinga, 6 November 2026). A Salix care pathway pilot raised hepatic encephalopathy treatment rates from 60.2% to 64.9% (Benzinga, 12 October 2026).

Bear case

• Debt remains the dominant fact. Total debt at principal was $20,168 million at 30 September 2026, and nine-month interest expense was $1,196 million (company release). Principal fell by about $71 million from $20,239 million at 30 June 2026, so interest absorbs a large share of operating gains.
• Management flagged fourth-quarter headwinds. A summary of the 28 October 2026 earnings call by The Cerbat Gem says gross-to-net accrual adjustments should cut fourth-quarter revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points. Xifaxan channel inventory normalisation could remove at least another 300 basis points of revenue growth.
• Salix assets are impaired. The 10-Q for the period ended 30 June 2026 recorded a $1,426 million goodwill impairment for Salix, and the Xifaxan intangible carried $808 million with about 18 months of remaining life.
• The price sits above part of the target range. The $8.35 close on 11 November 2026 is above Jefferies' $8 target and below Barclays' $9 and RBC's $10. Jefferies' Hold and RBC's Sector Perform ratings are neutral, so the raised targets follow the share price rather than lead it.
• Bausch + Lomb has an interim CEO. Brent Saunders left on 12 October 2026, and Thomas Appio, also Bausch Health's CEO, became interim CEO (Bausch + Lomb 8-K). No permanent successor has been named in company news reviewed.

Price setup

The shares closed at $8.35 on 11 November 2026. The 52-week intraday high is $9.04, set on 29 October 2026, the day after the results. The 52-week closing low is $4.43 on 24 July 2026, so the shares have nearly doubled from that close.

Closes since the report have held in a narrow range. They were $8.34 on 4 November 2026, $7.96 on 5 November 2026, $8.18 on 6 November 2026, $8.40 on 9 November 2026, $8.29 on 10 November 2026 and $8.35 on 11 November 2026. The last close is 28% above the 200-day average of $5.77 and about 28% above the 50-day average of $6.51.

The $50 million share repurchase program authorised on 28 October 2026 is sized to offset dilution from employee equity compensation, so it adds no net reduction in share count. SEC Form 4 filings show three directors received share grants at $5.83 on 30 September 2026, and President, US Pharma Aimee Lenar sold 36,827 shares at $7.03 on 19 August 2026 under a Rule 10b5-1 plan. No insider purchases or sales appear in Form 4 filings since the results. No earnings date falls within the next 30 days.

Catalysts ahead

• ~November 2026 (est.): Redemption of about $643 million of 8.500% senior notes due 2027, announced 28 October 2026; completion date not disclosed. Retires a near-term maturity using part of the $2,485 million cash balance.
• ~February 2027 (est.): Fourth-quarter 2026 results (outside the 30-day window). First test of the raised guidance against the fourth-quarter headwinds management described on the 28 October 2026 call.

What would change the view

A daily close below $7.00, which would unwind a large part of the three-month rally. Full-year 2026 adjusted EBITDA excluding Bausch + Lomb below the $3.225 billion low end of the raised guidance would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Fourth-quarter headwinds from gross-to-net accruals and Xifaxan channel inventory are larger than described and pull full-year results toward the low end of guidance. Confirmed by: fourth-quarter revenue and adjusted EBITDA growth below the 800 and 1,400 basis-point headwinds management flagged on 28 October 2026.
• Debt of about $20.2B absorbs operating gains and delays the Bausch + Lomb separation. Confirmed by: debt principal at the next quarter-end above $20,168 million, or a filing saying leverage targets for separation remain unmet.
• Further Salix weakness impairs the assets behind the turnaround. Confirmed by: a filing recording an impairment beyond $1,426 million of goodwill or a write-down of the $808 million Xifaxan intangible.
• The share price has run ahead of neutral-rated analyst targets after a 31.7% three-month gain. Confirmed by: covering firms cutting targets after the fourth-quarter report, or the Jefferies $8 target staying below the share price without a raise.
• Bausch + Lomb leadership uncertainty delays the separation or weakens its results, which feed Bausch Health's consolidated figures. Confirmed by: a Bausch + Lomb guidance cut, or no permanent CEO named by the fourth-quarter report.

What it trades with

Bausch Health consolidates Bausch + Lomb (ticker BLCO), so BLCO results, guidance and share price feed its consolidated figures. The company's debt load makes the shares sensitive to credit-market conditions and interest-rate moves, and the equity moves by a large percentage when enterprise value changes. Xifaxan prescription trends and any generic-competition news drive the Salix part of the business.